TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer

Norikatsu Miyoshi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Toshiki Hitora, Mitsuyoshi Tei, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway. Methods: We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase-polymerase chain reaction (P = .015). Results: Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth. Conclusions: The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.

Original languageEnglish
Pages (from-to)967-972
Number of pages6
JournalAnnals of Surgical Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 1 2010

Fingerprint

Colorectal Neoplasms
Therapeutics
transglutaminase 2
Cell Line
Growth
Reverse Transcriptase Polymerase Chain Reaction
Real-Time Polymerase Chain Reaction
Cell Survival
Survival Rate
Gene Expression
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer. / Miyoshi, Norikatsu; Ishii, Hideshi; Mimori, Koshi; Tanaka, Fumiaki; Hitora, Toshiki; Tei, Mitsuyoshi; Sekimoto, Mitsugu; Doki, Yuichiro; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 17, No. 4, 01.04.2010, p. 967-972.

Research output: Contribution to journalArticle

Miyoshi, N, Ishii, H, Mimori, K, Tanaka, F, Hitora, T, Tei, M, Sekimoto, M, Doki, Y & Mori, M 2010, 'TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer', Annals of Surgical Oncology, vol. 17, no. 4, pp. 967-972. https://doi.org/10.1245/s10434-009-0865-y
Miyoshi, Norikatsu ; Ishii, Hideshi ; Mimori, Koshi ; Tanaka, Fumiaki ; Hitora, Toshiki ; Tei, Mitsuyoshi ; Sekimoto, Mitsugu ; Doki, Yuichiro ; Mori, Masaki. / TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 4. pp. 967-972.
@article{59454f7dce744a6d911730a09dd5ec94,
title = "TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer",
abstract = "Background: Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway. Methods: We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase-polymerase chain reaction (P = .015). Results: Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth. Conclusions: The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.",
author = "Norikatsu Miyoshi and Hideshi Ishii and Koshi Mimori and Fumiaki Tanaka and Toshiki Hitora and Mitsuyoshi Tei and Mitsugu Sekimoto and Yuichiro Doki and Masaki Mori",
year = "2010",
month = "4",
day = "1",
doi = "10.1245/s10434-009-0865-y",
language = "English",
volume = "17",
pages = "967--972",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer

AU - Miyoshi, Norikatsu

AU - Ishii, Hideshi

AU - Mimori, Koshi

AU - Tanaka, Fumiaki

AU - Hitora, Toshiki

AU - Tei, Mitsuyoshi

AU - Sekimoto, Mitsugu

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway. Methods: We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase-polymerase chain reaction (P = .015). Results: Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth. Conclusions: The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.

AB - Background: Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway. Methods: We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase-polymerase chain reaction (P = .015). Results: Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth. Conclusions: The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.

UR - http://www.scopus.com/inward/record.url?scp=77952091768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952091768&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0865-y

DO - 10.1245/s10434-009-0865-y

M3 - Article

C2 - 20033322

AN - SCOPUS:77952091768

VL - 17

SP - 967

EP - 972

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -